XRCC1 and breast carcinoma: Nevertheless, the number of patients assessed is relatively small, so further analyses using an independent cohort of breast cancer patients are required to confirm the apparent association between an early acute reaction and late fibrosis/atrophy, and between the additional 15 Gy boost, XRCC1 (R399Q) and telangiectasia.